M
Mark A. Marzinke
Researcher at Johns Hopkins University School of Medicine
Publications - 187
Citations - 6072
Mark A. Marzinke is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Pre-exposure prophylaxis & Medicine. The author has an hindex of 31, co-authored 158 publications receiving 4416 citations. Previous affiliations of Mark A. Marzinke include Johns Hopkins University & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women
Jeanne M. Marrazzo,Gita Ramjee,Barbra A. Richardson,Kailazarid Gomez,Nyaradzo Mgodi,Gonasagrie Nair,Thesla Palanee,Clemensia Nakabiito,Ariane van der Straten,Lisa M. Noguchi,Craig W. Hendrix,James Y. Dai,S. Ganesh,Baningi Mkhize,Marthinette Taljaard,Urvi M. Parikh,Jeanna M. Piper,Benoît Mâsse,Benoît Mâsse,Cynthia I. Grossman,James F. Rooney,Jill L. Schwartz,Heather Watts,Mark A. Marzinke,Sharon L. Hillier,Ian McGowan,Z. Mike Chirenje +26 more
TL;DR: None of the drug regimens evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis, and adherence to study drugs was low.
Journal ArticleDOI
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women
Jared M. Baeten,Thesla Palanee-Phillips,Elizabeth R. Brown,Elizabeth R. Brown,Katie Schwartz,Lydia Soto-Torres,Vaneshree Govender,Nyaradzo Mgodi,Flavia Matovu Kiweewa,Gonasagrie Nair,Felix Mhlanga,Samantha Siva,Linda-Gail Bekker,Nitesha Jeenarain,Zakir Gaffoor,Francis Martinson,Bonus Makanani,Arendevi Pather,Logashvari Naidoo,Marla Husnik,Marla Husnik,Barbra A. Richardson,Barbra A. Richardson,Urvi M. Parikh,John W. Mellors,Mark A. Marzinke,Craig W. Hendrix,Ariane van der Straten,Ariane van der Straten,Gita Ramjee,Zvavahera M. Chirenje,Clemensia Nakabiito,Taha E. Taha,Judith G. Jones,Ashley J Mayo,Rachel Scheckter,Jennifer Berthiaume,Edward Livant,Cindy Jacobson,Patrick Ndase,Rhonda White,Karen Patterson,Donna Germuga,Beth Galaska,Katherine E. Bunge,Devika Singh,Daniel W. Szydlo,Elizabeth T. Montgomery,Barbara S. Mensch,Kristine Torjesen,Cynthia I. Grossman,Nahida Chakhtoura,Annalene Nel,Zeda F. Rosenberg,Ian McGowan,Sharon L. Hillier +55 more
TL;DR: A monthly vaginal ring containing dapivirine reduced the risk of HIV-1 infection among African women, with increased efficacy in subgroups with evidence of increased adherence.
Journal ArticleDOI
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz,Deborah Donnell,Meredith E. Clement,Brett Hanscom,Leslie Cottle,Lara E. Coelho,Robinson Cabello,Suwat Chariyalertsak,Eileen F. Dunne,Ian Frank,Jorge A Gallardo-Cartagena,Aditya H Gaur,Pedro Gonzales,Ha V Tran,Juan C Hinojosa,Esper G Kallas,Colleen F Kelley,Marcelo H. Losso,J Valdez Madruga,Keren Middelkoop,Nittaya Phanuphak,Breno Santos,Omar Sued,Javier Valencia Huamaní,Edgar T. Overton,Shobha Swaminathan,Carlos del Rio,Roy M. Gulick,Paul G. Richardson,Philip Sullivan,Estelle Piwowar-Manning,Mark A. Marzinke,Craig W. Hendrix,Maoji Li,Zhe Wang,Jeanne M. Marrazzo,Eric S. Daar,Aida Asmelash,Todd T. Brown,Peter J. Anderson,Susan H. Eshleman,Marcus Bryan,Cheryl Blanchette,Jonathan Lucas,Christina Psaros,Steven A. Safren,Jeremy Sugarman,Hyman M. Scott,Joseph J. Eron,Sheldon D. Fields,Nirupama Sista,Kailazarid Gomez-Feliciano,Andrea Jennings,Ryan Kofron,Timothy H. Holtz,Katherine Shin,James F. Rooney,Kimberly Y. Smith,William Spreen,David J. Margolis,Alex R. Rinehart,Adeola Adeyeye,Myron S. Cohen,Marybeth McCauley,Beatriz Grinsztejn,Hptn (PopART) Study Team +65 more
TL;DR: In this paper, safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preve...
Journal ArticleDOI
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda.
Jared M. Baeten,Renee Heffron,Lara Kidoguchi,Nelly Mugo,Nelly Mugo,Elly Katabira,Elizabeth A. Bukusi,Elizabeth A. Bukusi,Stephen Asiimwe,Jessica E. Haberer,Jennifer F Morton,Kenneth Ngure,Nulu Bulya,Josephine Odoyo,Edna Tindimwebwa,Craig W. Hendrix,Mark A. Marzinke,Norma C. Ware,Monique A. Wyatt,Susan Morrison,Harald S. Haugen,Andrew Mujugira,Deborah Donnell,Deborah Donnell,Connie Celum +24 more
TL;DR: Integrated delivery of time-limited PrEP until sustained ART use in African HIV-1-serodiscordant couples was feasible, demonstrated high uptake and adherence, and resulted in near elimination of HIV- 1 transmission, with an observed HIV incidence of <0.5% per year compared to an expected incidence of >5%" per year.
Journal ArticleDOI
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)
Craig W. Hendrix,Adriana Andrade,Namandjé N. Bumpus,Angela D. M. Kashuba,Mark A. Marzinke,Ayana Moore,Peter L. Anderson,Lane R. Bushman,Edward J. Fuchs,Ilene Wiggins,Christine Radebaugh,Heather M.A. Prince,Rahul P. Bakshi,Ruili Wang,Paul G. Richardson,Eugenie Shieh,Laura McKinstry,Xin Li,Deborah Donnell,Vanessa Elharrar,Kenneth H. Mayer,Kristine B. Patterson +21 more
TL;DR: Steady-state daily dosing serum TFV and PBMC TFV-DP was consistent with highly effective PrEP clinical trials and TFV/FTC was consistently quantifiable 2 weeks after the last dose for the ≥4/week regimens.